Table 1.
Clinical characteristics of the studied patient cohort.
| Parameters | All Patients (N = 58) |
|---|---|
| Age, median (range) | 71 (49–83) |
| Gender, male, N (%) | 40 (69) |
| Previous loco-regional treatments, N (%) | 31(53) |
| Previous liver surgery, N (%) | 22 (38) |
| Etiology (%) | |
| HCV | 21 (36) |
| HBV | 5 (9) |
| Non-viral # | 32 (55) |
| Child–Pugh Score A, N (%) | 57 (98) |
| Child–Pugh Score B, N (%) | 1 (1.7) |
| Baseline bilirubin levels, median, mg/dL (range) | 0.70 (0.30–2.20) |
| Baseline ALT levels, median, mg/dL (range) | 37 (11–147) |
| Baseline AST levels, median, mg/dL (range) | 40 (15–239) |
| Patients with abnormal ALT/AST values (%) | 17/23 (29.3/39.6) |
| Baseline INR, median (range) | 1.11 (0.90–1.50) |
| Albi grade, N (%) | |
| 1 | 48 (82) |
| 2 | 10 (18) |
| Median time from HCC diagnosis to treatment start with immune checkpoint inhibitors, days (range) | 615 (29–8191) |
| Line of treatment with ICIs, N (%) | |
| First | 19 (33) |
| Second | 33 (57) |
| Third | 6 (10) |
| Treatment received, N (%) | |
| Anti-PD-1/PD-L1 monotherapy | 20(34) |
| Anti-PD1/PD-L1 + anti-CTLA-4 | 15(26) |
| Anti-PD1/PD-L1 + anti-CTLA4 + targeted agents | 5(9) |
| Anti-PD1/PD-L1 + targeted agents | 18(31) |
Abbreviations: HCV, chronic hepatitis C; HBV, chronic hepatitis B; Albi, albumin-bilirubin; PD-L1, programmed cell death receptor ligand 1; PD-1, programmed cell death receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4. # Includes: alcohol (N = 12), hemochromatosis (N = 1), non-alcoholic fatty liver disease (N = 2), unknown (N = 17).